MA
DFTX

Montag & Associates’s Definium Therapeutics DFTX Stock Holding History

Montag & Associates’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3
Closed – – 975
2022
Q3 		$0 Sell
3
-1
-25% -$10 ﹤0.01% 882
2022
Q2 		$0 Hold
4
– – ﹤0.01% 844
2022
Q1 		$0 Hold
4
– – ﹤0.01% 871
2021
Q4 		$0 Hold
4
– – ﹤0.01% 892
2021
Q3 		$0 Hold
4
– – ﹤0.01% 884
2021
Q2 		$0 Buy
+4
New +$210 ﹤0.01% 879

Other funds holding DFTX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Montag & Associates's DFTX Position: Q4 2022 in Review

Montag & Associates sold out of Definium Therapeutics (DFTX) in Q4 2022, closing a stake of 3 shares.

Montag & Associates first reported a position in DFTX in Q2 2021 and held it in 6 quarters. The position peaked at $0 in Q3 2022. 104 funds tracked by Wall St. Rank hold DFTX as of Q4 2022.

  • Montag & Associates reported no remaining Definium Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Montag & Associates sold 3 Definium Therapeutics shares in Q4 2022.
  • Montag & Associates first reported a position in Definium Therapeutics in Q2 2021 and held it in 6 quarters.
  • Montag & Associates's Definium Therapeutics position peaked at $0 in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2022.

Based on Montag & Associates's 13F filing for Q4 2022, filed 2 Feb 2023.